Treatment of Urinary Tract Infection Symptoms
For uncomplicated UTI symptoms in women, initiate nitrofurantoin 5 days, trimethoprim-sulfamethoxazole 3 days (if local resistance <20%), or fosfomycin single dose as first-line therapy, with treatment duration generally no longer than 7 days. 1, 2, 3
Diagnostic Approach
Obtain Urine Culture Before Treatment
- Obtain urinalysis, urine culture and sensitivity with each symptomatic acute cystitis episode prior to initiating treatment in patients with recurrent UTIs. 1
- In women with typical symptoms (dysuria, frequency, urgency, suprapubic pain) without vaginal discharge, self-diagnosis is accurate enough to proceed with empiric treatment without further testing if this is a first or infrequent episode. 3, 4
- Reserve urine culture for women with recurrent infection, treatment failure, history of resistant organisms, or atypical presentation. 3
- Dysuria is the most diagnostic symptom, with >90% accuracy for UTI in young women when vaginal irritation or discharge is absent. 1
When Culture Results Are Pending
- Patient-initiated treatment (self-start therapy) may be offered to select patients with recurrent UTIs while awaiting culture results. 1
- Use prior culture data if available to guide empiric antibiotic selection. 1
First-Line Antibiotic Treatment
Recommended Agents (in order of preference)
Use first-line therapy dependent on local antibiogram: 1
- Nitrofurantoin for 5 days - preferred due to low resistance rates and minimal collateral damage 1, 2, 3
- Trimethoprim-sulfamethoxazole for 3 days - only if local resistance <20% 1, 3
- Fosfomycin single 3-gram dose 1, 3
Treatment Duration
- Treat acute cystitis episodes with as short a duration as reasonable, generally no longer than 7 days. 1
- Three-day therapy is optimal for most uncomplicated UTIs, balancing efficacy with minimizing resistance development. 3
Special Populations
Men with UTI Symptoms
- Always obtain urine culture and susceptibility testing before initiating therapy. 5
- Treat for 14 days when prostatitis cannot be excluded. 5
- First-line options include trimethoprim, trimethoprim-sulfamethoxazole, or nitrofurantoin for 7 days minimum. 5, 3
- Consider evaluation for underlying urological abnormalities or complicating factors. 5
Postmenopausal Women with Recurrent UTIs
- Consider vaginal estrogen with or without lactobacillus-containing probiotics as preventive therapy. 1
- This approach addresses the underlying risk factor of vaginal atrophy. 1
Premenopausal Women with Post-Coital Infections
- Consider low-dose antibiotic within 2 hours of sexual activity for 6-12 months. 1
Second-Line Options
When First-Line Agents Are Inappropriate
- Fluoroquinolones should be avoided if patient used them in last 6 months or local resistance >10%. 2, 5
- Beta-lactams (amoxicillin-clavulanate) can be used but have higher rates of collateral damage. 1, 6
- For culture-resistant organisms requiring parenteral therapy, use culture-directed antibiotics for no longer than 7 days. 1
Critical Pitfalls to Avoid
Do NOT Treat Asymptomatic Bacteriuria
- Strongly avoid treating asymptomatic bacteriuria in non-pregnant patients. 1
- Treatment of asymptomatic bacteriuria fosters antimicrobial resistance and increases recurrent UTI episodes. 1
- Omit surveillance urine testing in asymptomatic patients with recurrent UTIs. 1
Antimicrobial Stewardship Principles
- Combine knowledge of local antibiogram with selection of agents having least impact on normal vaginal and fecal flora. 1
- Avoid classifying patients with recurrent UTIs as "complicated" unless they have structural/functional abnormalities, as this leads to unnecessary broad-spectrum antibiotic use. 1
- Consider antibiotic resistance patterns in both the individual patient and community. 1, 2
When Symptoms Persist
- If symptoms persist despite treatment, repeat urine culture to assess for ongoing bacteriuria before prescribing additional antibiotics. 1
- Consider alternative diagnoses including vaginitis, vulvar lesions, physical/chemical irritants, or sexually transmitted diseases. 7